Diabetes medications, Type 1 diabetes, Type 2 diabetes

LIVINGLIVING

separate injections of Symlin (pramlintide)

and Humulin.

In people without diabetes, the

hormones insulin and amylin are secreted

by pancreatic beta cells and act together

to control blood sugar. By combining two

synergistic agents, ADO09 is designed

to deliver better postprandial glycemic

control for people with diabetes without

the added burden of having to inject two

different treatments.

During the trial, the treatment was

reported as well tolerated, and Adocia is

due to launch a Phase 1/2, outpatient,

three-week trial of ADO09 shortly.

Treatments for Type 2

Injectable treatments

Ozempic (semaglutide), developed by

Novo Nordisk, is a GLP-1 analogue

injection which mimics a hormone

produced in the gut that lowers post-meal

blood sugar levels. Taken once-weekly, it

also slows down digestion. Now available

in the UK, it received European approval

in February 2018 and in 2017 in the US.

Results from trials showed that

Ozempic had positive impacts on blood

sugar and weight loss, and also showed

benefits to cardiovascular health.

Ozempic is recommended for people

to use in conjunction with a healthy,

balanced diet and regular exercise when

metformin is considered inappropriate. As

with any medication, there are possible side

effects, and these include inflammation of

the pancreas, changes in vision, kidney

problems and allergic reactions.

Tablets

Novo Nordisk has also developed an oral

version of semaglutide (in 7mg and 14mg),

and results from a study called PIONEER,

involving 9,543 adults with Type 2 diabetes

has shown that it demonstrates superior

HbA1c and weight loss compared to

Januvia (sitagliptin 100mg). In the US, the

company has submitted applications to

the FDA and hopes for the oral version to

be approved alongside diet and exercise

to improve blood sugar control in adults

with Type 2 diabetes as well as being able

to state cardiovascular benefits.

Amylin: A peptide hormone co-secreted with insulin from the

pancreatic beta-cell, which is absent or reduced in people with

diabetes. Amylin inhibits glucagon secretion, delays gastric

emptying and creates a feeling of fullness.

GLP-1 analogue: Also known as incretin memetics, they

increase the levels of hormones called 'incretins'. Incretins help

to produce more insulin when needed and reduce the amount of

glucose produced by the liver when it's not needed. These drugs

lessen the rate at which the stomach digests food and empties,

and can also reduce appetite.

SGLT2 inhibitors: These reduce the amount of glucose being

absorbed in the kidneys so that it is passed out in the urine, and

also reduces the amount of glucose in the blood.

Taking control

We know that as tech gets better and

more accessible it has a vital place to

help manage various health conditions -

particularly when it comes to diabetes. At

a conference in Berlin in February 2019,

Sanofi reported on using technology to

support people with diabetes to manage

their own health, looking specifically at

insulin dose management during the first

12 weeks of insulin treatment. With the

understanding that people play a key role

in managing their dose adjustment in this

timeframe,

Sanofi's Take Control study involved

participants in 10 pilot programmes and

four active commercial launches across

the world, using a blood glucose meter

(MyStar DoseCoach) and a smartphone

app (My Dose Coach), along with

collaborations with Voluntis smartphone

app. These tools take people's daily blood

sugar readings to suggest the insulin

dose, which is aligned with a blood sugar

target agreed by their doctor.

A pilot study in India involving 137

adults with Type 2 took their fasting blood

sugar levels each morning and entered this

reading into the My Dose Coach app. The

app then used the data to recommend

a daily dose of insulin. Over a 12-week

period, average blood sugar levels were

decreased from 9.9% to 7.2%, while 38%

of the participants achieved less than the

recommended 7%.

*Journalist Angela Coffey is a former Editor of Diabetes UK's Balance magazine.

Glossary

Index

  1. Desang diabetes magazine diabetes information
  2. Dexcom CGM, continuous glucose monitoring
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes magazine diabetes news
  7. Page 0007
  8. Page 0008
  9. Medtronic Minimed 670G hybrid closed loop insulin pump
  10. Connected insulin pens, Novo Nordisk, Timesulin, Big Foot Biomedical, InsulCheck
  11. Connected insulin pens, Novo Nordisk, Timesulin, Big Foot Biomedical, InsulCheck
  12. Desang diabetes magazine diabetes diet
  13. Desang diabetes kitbags
  14. Page 0014
  15. HbA1c home test, A1C now, BHR Pharmaceuticals Ltd, home use A1C test, home use HbA1c test
  16. Page 0016
  17. Page 0017
  18. JDRF stem cell encapsulation
  19. Omnipod Insulet insulin pump with insulin pods, podders
  20. Desang Diabetes Magazine, free diabetes magazine, living with diabetes
  21. Desang Diabetes Magazine, free diabetes magazine, living with diabetes
  22. Blood test meters, nothing beats a blood test, CGM
  23. Blood test meters, nothing beats a blood test, CGM
  24. Ascensia Contour Next One Diabetes blood test meters
  25. ia Contour Next One Diabetes blood test meters
  26. Blood test meters, blood glucose meters, Kinetik Wellbeing, Ypsomed mylife Unio
  27. Ypsomed MyLife Diabetes care blood glucose monitoring systems
  28. Diabetes medications, Type 1 diabetes, Type 2 diabetes
  29. Diabetes Research and Wellness Foundation, DRWF Wellness Days
  30. Diabetes medications, Type 1 diabetes, Type 2 diabetes
  31. Ascensia Contour Next One Diabetes blood test meters
  32. Kit that's coming soon MyGrams smartphone scales
  33. Kit that's coming soon MyGrams smartphone scales
  34. Making Carbs count: Counting carbs for the diabetic diet
  35. Making Carbs Count teff
  36. Making Carbs Count teff
  37. Accu-Chek Insight insulin pump for Animas users
  38. Desang Diabetes Magazine, free diabetes magazine, living with diabetes

Related Issues